- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01529710
Safety and Efficacy of Mirazid for Schistosomiasis Treatment (PHAR0211)
Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study
Clinical Trial Phase:Phase III
Primary Objectives:
- Compare Mirazid and Praziquantel cure rates for both Schistosoma species.
- Compare Mirazid and Praziquantel effect in lowering the intensity of infection for both Schistosoma species.
Secondary Objective:Identify and compare the types and severity of side and adverse effects between the Mirazid and Praziquantel.
Study Population:200 Schistosomiasis infected persons of both types of Schistosomiasis aged from 15-35 years. Those subjects will be selected from among those screened.Subjects will include both genders excluding chronically ill such as chronic liver disease patients and those with both types of Schistosomiasis.
Recruitment Period:3 months and subjects follow up for another 3 months followed by 3 months for statistical analysis and report writing Study Duration: Total study duration is expected to be 9 months: 3 months for recruitment, 3 months for follow up and 3 months for data management and report writing.
Endpoints: Will be measured at 3 months of successful administration of treatment either Mirazid or Praziquantel as per the randomization scheme. By then, final assessment of the response to treatment will be done by examining urine or stool of the subject for presence of Schistosoma eggs and its density if found.
Three negative urine or stool samples collected 2-days apart at 12 weeks post treatment will indicate treatment success. One positive sample collected at week 12 will indicate infection with Schistosomiasis.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Gharbiya, Egypt
- Tanta Health Unit
-
Giza, Egypt
- Health Unit of Atfeeh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adolescent and young adults aged 15-30 years
- Positive for Schistosoma infection of any type.
Exclusion Criteria:
- Mixed Schistosoma infection of both types
- History of administration of treatment for Schistosoma infection in the last 6 months prior to the study.
- Severely ill patients
- Advanced chronic liver disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mirazid
Mirazid is an antischistosomal drug available in the local Egyptian market since 2001 (Mirazid®).
It originates from Myrrh a medicinal herb that has been used for thousands of years.
Myrrh (Arabian or Somali Myrrh) is an oleo-gum resin, obtained from the stem of various species of Commiphora (Burseraceae) growing in northeast Africa and Arabia.
|
Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose.
Subjects will be evaluated for success of treatment at 12 weeks of treatment.
Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.
Other Names:
|
Active Comparator: Praziquantel
Tablets
|
Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose.
Subjects will be evaluated for success of treatment at 12 weeks of treatment.
Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Compare Mirazid and Praziquantel cure rates for both Schistosoma species, and effect in lowering the intensity of infection for both Schistosoma species.
Time Frame: 9 months
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Identify and compare the types and severity of side and adverse effects between the Mirazid and Praziquantel.
Time Frame: 9 months
|
9 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ayat A Haggag, MD, Ministry of Health
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Mirazid2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schistosomiasis Mansoni
-
IRCCS Sacro Cuore Don Calabria di NegrarActive, not recruiting
-
Leiden University Medical CenterCompletedSchistosomiasis | Schistosomiasis MansoniNetherlands
-
Oswaldo Cruz FoundationUniversidade Federal de Pernambuco; World Health OrganizationCompletedSchistosomiasis Mansoni
-
Leiden University Medical CenterCompletedSchistosomiasis | Schistosoma MansoniNetherlands
-
Rhode Island HospitalLondon School of Hygiene and Tropical Medicine; Medical Research Council; University... and other collaboratorsRecruitingSchistosomiasis | Schistosomiasis Mansoni | Schistosoma Japonicum InfectionUganda, United Kingdom
-
Enaiblers ABMinistry of Health, Uganda; Jimma University; Ghent University, BelgiumNot yet recruitingSchistosomiasis Mansoni | Soil Transmitted Helminths
-
DBL -Institute for Health Research and DevelopmentCompletedSchistosomiasis Mansoni | Circulating Cathodic Antigen Urine Based DipstickKenya
-
Oswaldo Cruz FoundationRecruitingVaccination; Infection | Schistosomiasis Mansoni | Schistosomiasis HaematobiumSenegal
-
University of TorontoUVRI-IAVI HIV Vaccine Program, UgandaCompletedHIV | Schistosomiasis MansoniUganda
-
Makerere UniversityUniversity of CopenhagenCompleted
Clinical Trials on Myrrh
-
Cairo UniversityNot yet recruiting
-
King Abdulaziz UniversityCompletedGingivitis | Dental PlaqueSaudi Arabia